focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing

14 Oct 2015 17:13

RNS Number : 3070C
PuriCore Plc
14 October 2015
 



 

 

PuriCore plc

("PuriCore" or the "Company")

 

Director Dealing

 

 

14 October 2015 - PuriCore plc (AIM: PURI), an international company focused on applying its proprietary hypochlorous acid platform technology to unmet needs in human health, announces that, on 14 October 2015, the Director named below notified the Company that he had purchased ordinary shares of 10p each in the share capital of the Company ("Shares").

 

 

Name

Date purchased

Number of Shares purchased

Purchase price of Shares

Shareholding following the purchase

% of issued share capital

Daniel Hegglin Non-Executive Director

13 October 2015

500,000

18p

5,909,091

11.79%

 

-Ends-

 

Enquiries:

 

PuriCore plc

+44 (0) 20 3727 1000

 

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

 

FTI Consulting

+44 (0) 20 3727 1000

 

Simon Conway / Mo Noonan / Victoria Foster Mitchell

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

 

Aubrey Powell / Jen Boorer / Thomas Smale

 

 

About PuriCore

PuriCore is an international company, focused on developing and commercialising products based on its proprietary hypochlorous acid platform technology, to address significant unmet needs in human health. PuriCore's products are currently used in two broad market segments: Supermarket Retail and Health Sciences. PuriCore's products do not cause harm to human or animal life or to the environment. The Group is headquartered in Malvern, Pennsylvania.

 

In the Supermarket Retail segment, PuriCore's products are used by customers to enhance quality and freshness of produce and floral products. Product offerings include the Sterilox® Fresh Systems (capital equipment) that are installed at customer locations and allow for generation of the solution as needed at the store. ProduceFresh® is the Company's concentrate bottled version of the solution for produce application. Customers use FloraFresh®, also sold as a concentrate in bottled form, to improve the freshness of cut flowers. ProduceFresh and FloraFresh are diluted for use by customers through the Company's concentrate delivery systems.

 

In Health Sciences, PuriCore offers a range of products to manage a variety of skin and wound conditions under a medical device registration.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGGGPGUUPAGQC
Date   Source Headline
21st Nov 20177:00 amRNSRealm: Preclinical Data on PR022 Published
17th Nov 20177:00 amRNSDirectorate Change
2nd Nov 20177:00 amRNSRealm Therapeutics to Present at BIO-Europe® 2017
30th Oct 20177:00 amRNSRealm Presents Data at ACAAI Scientific Meeting
18th Oct 20177:00 amRNSHolding(s) in Company
18th Oct 20177:00 amRNSBlock Listing Application
17th Oct 20176:28 pmRNSHolding(s) in Company
16th Oct 20173:39 pmRNSHolding(s) in Company
16th Oct 20177:00 amRNSRealm Therapeutics to speak at BIO Investor Forum
13th Oct 20172:20 pmRNSHolding(s) in Company
13th Oct 20172:17 pmRNSHolding(s) in Company
12th Oct 20175:48 pmRNSHolding(s) in Company
12th Oct 20173:07 pmRNSRealm Therapeutics: Completion of £19.3m Placing
12th Oct 201711:04 amRNSHolding(s) in Company
12th Oct 201710:58 amRNSHolding(s) in Company
9th Oct 201711:35 amRNSResult of General Meeting
22nd Sep 20177:00 amRNSProposed Placing to raise £19.3 million
22nd Sep 20177:00 amRNSInterim Results
21st Sep 20176:01 pmRNSProposed Placing to raise £19.3 million
21st Sep 20176:00 pmRNSInterim Results
11th Sep 20177:00 amRNSFDA Permits PR013 to Proceed to Phase II Trial
7th Sep 20177:00 amRNSConference Presentation
18th Aug 20177:00 amRNSBlock listing Interim Review
2nd Aug 20177:00 amRNSSubmission of Investigational New Drug Application
6th Jul 20177:00 amRNSPresentation at World Congress on Inflammation
14th Jun 20177:09 amRNSPresentation at 2017 Marcum Microcap Conference
6th Jun 201711:05 amRNSResult of AGM
11th May 201712:21 pmRNSNotice of AGM
23rd Mar 20172:57 pmRNSAnnual Report and Accounts Available
23rd Mar 20177:00 amRNSFinal Results and Business Update
6th Mar 20177:00 amRNSConference Presentation
28th Feb 20177:00 amRNSFDA permits PR022 to Proceed to Phase 2 Trial
20th Feb 20177:00 amRNSBlock listing Interim Review
13th Feb 20177:00 amRNSPresentation at BIO CEO & Investor Conference
30th Jan 20177:00 amRNSResearch Update - Submission of first IND
5th Jan 20177:00 amRNSConference Presentations
4th Jan 20177:00 amRNSGrant of Options
21st Dec 20167:00 amRNSPDMR dealing
16th Dec 20167:00 amRNSIvan Gergel appointed as Non-Executive Director
7th Dec 20167:00 amRNSChange of name to Realm Therapeutics
18th Nov 20167:00 amRNSGrant of Options
17th Nov 20167:00 amRNSHolding(s) in Company
16th Nov 20167:00 amRNSDevelopment Programmes Update & Company Renaming
10th Oct 20167:00 amRNSCompletion of Supermarket Retail Business Disposal
7th Oct 20165:52 pmRNSCompletion of Supermarket Retail Business Disposal
6th Oct 201611:43 amRNSResult of General Meeting
23rd Sep 20162:47 pmRNSDirector/PDMR Dealing
22nd Sep 20162:15 pmRNSGrant of Options
20th Sep 20167:00 amRNSProposed Disposal of Supermarket Retail Business
20th Sep 20167:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.